Other languages TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
0.82 ^USD	+15.98%		+49.12%	-87.56%

22/04	Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	CI
22/04	Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors	15/04
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer	28/03
TransCode Therapeutics, Inc. and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment	11/03
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode?s RIG-I Agonist Immunotherapeutic	20/02
TransCode Therapeutics, Debiopharm Collaborate to Develop Nucleic Acid Therapies for Cancer	30/01
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer	29/01
Sector Update: Health Care Stocks Softer Late Thursday Afternoon	19/01
Sector Update: Health Care	19/01
Top Midday Decliners	19/01
TransCode Therapeutics' Shares Tumble After Pricing Public Offering	19/01
Sector Update: Health Care Stocks Fall Premarket Tuesday	16/01
MORNING BRIEFING - USA/Asien	15/01
TransCode Reports Additional Restructuring Steps; Chief Executive Michael Dudley to Retire	13/01
TransCode Therapeutics, Inc. Announces CEO Changes	13/01
TransCode Therapeutics, Inc. Announces Management Changes	13/01
TransCode Therapeutics, Inc. Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with Its Lead Candidate, TTX-MC138	12/12
TransCode Therapeutics, Inc. to Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium	05/12
TransCode Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
TransCode Therapeutics Gets Conditional Extension for Continued Listing on Nasdaq; Shares Tumble	27/23/27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Other languages

Filters